| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 19 | 2020 | 8843 | 1.71 | Why? |
| Republic of Korea | 32 | 2021 | 5858 | 1.34 | Why? |
| Bunyaviridae Infections | 2 | 2019 | 107 | 1.33 | Why? |
| Triazoles | 2 | 2018 | 440 | 1.04 | Why? |
| Microbial Sensitivity Tests | 5 | 2020 | 2886 | 0.94 | Why? |
| Phlebotomus Fever | 2 | 2018 | 44 | 0.87 | Why? |
| Bacterial Toxins | 2 | 2019 | 185 | 0.85 | Why? |
| Anthrax Vaccines | 1 | 2019 | 9 | 0.81 | Why? |
| Blood Culture | 2 | 2019 | 308 | 0.75 | Why? |
| Glucuronosyltransferase | 1 | 2018 | 24 | 0.75 | Why? |
| Citrobacter freundii | 1 | 2018 | 14 | 0.74 | Why? |
| Scrub Typhus | 1 | 2019 | 68 | 0.72 | Why? |
| Antibodies, Viral | 15 | 2021 | 51949 | 0.69 | Why? |
| Anaplasmosis | 1 | 2017 | 21 | 0.68 | Why? |
| Mycobacterium avium Complex | 1 | 2017 | 61 | 0.67 | Why? |
| Antibodies, Neutralizing | 12 | 2021 | 25288 | 0.67 | Why? |
| Mycobacterium avium-intracellulare Infection | 1 | 2017 | 59 | 0.65 | Why? |
| Gram-Positive Bacteria | 1 | 2018 | 230 | 0.63 | Why? |
| Inhalation Exposure | 1 | 2021 | 405 | 0.63 | Why? |
| Antigens, Bacterial | 1 | 2019 | 330 | 0.62 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 552 | 0.61 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2017 | 260 | 0.55 | Why? |
| Bacteremia | 4 | 2019 | 1372 | 0.55 | Why? |
| Anti-Bacterial Agents | 6 | 2019 | 10083 | 0.54 | Why? |
| Sputum | 3 | 2021 | 1720 | 0.53 | Why? |
| T-Lymphocyte Subsets | 1 | 2021 | 1387 | 0.51 | Why? |
| Coronavirus Infections | 30 | 2020 | 253789 | 0.50 | Why? |
| Gram-Negative Bacteria | 1 | 2018 | 473 | 0.50 | Why? |
| Positron-Emission Tomography | 1 | 2018 | 802 | 0.48 | Why? |
| Antibody Formation | 3 | 2021 | 4038 | 0.47 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 952 | 0.45 | Why? |
| Oropharynx | 1 | 2020 | 1581 | 0.44 | Why? |
| Lymph Nodes | 1 | 2018 | 1060 | 0.43 | Why? |
| Enzyme-Linked Immunosorbent Assay | 8 | 2021 | 7868 | 0.43 | Why? |
| Immunity, Cellular | 3 | 2021 | 3614 | 0.43 | Why? |
| Lipids | 1 | 2018 | 1079 | 0.43 | Why? |
| Polymorphism, Genetic | 1 | 2018 | 1074 | 0.43 | Why? |
| Antifungal Agents | 2 | 2018 | 1828 | 0.42 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2018 | 1153 | 0.41 | Why? |
| Virus Shedding | 2 | 2018 | 5834 | 0.41 | Why? |
| Lymphocyte Activation | 1 | 2020 | 2742 | 0.41 | Why? |
| Plasma | 1 | 2020 | 1809 | 0.40 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.39 | Why? |
| Recombinant Proteins | 2 | 2021 | 3786 | 0.39 | Why? |
| Neutralization Tests | 4 | 2021 | 6698 | 0.38 | Why? |
| Phlebovirus | 3 | 2019 | 106 | 0.38 | Why? |
| Immunologic Memory | 1 | 2021 | 3362 | 0.38 | Why? |
| Immunity, Humoral | 2 | 2020 | 4849 | 0.37 | Why? |
| Whole Genome Sequencing | 1 | 2020 | 3239 | 0.37 | Why? |
| Anti-Infective Agents | 1 | 2020 | 1766 | 0.36 | Why? |
| Bacteria | 1 | 2019 | 1897 | 0.36 | Why? |
| Leukopenia | 2 | 2019 | 280 | 0.32 | Why? |
| Radiography, Thoracic | 3 | 2020 | 5486 | 0.32 | Why? |
| Adult | 38 | 2021 | 244371 | 0.31 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.31 | Why? |
| Male | 46 | 2021 | 367725 | 0.30 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.29 | Why? |
| Respiratory System | 1 | 2018 | 3213 | 0.29 | Why? |
| Female | 44 | 2021 | 380317 | 0.29 | Why? |
| Humans | 72 | 2021 | 930598 | 0.29 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.29 | Why? |
| Staphylococcal Infections | 3 | 2018 | 1099 | 0.28 | Why? |
| Young Adult | 23 | 2021 | 93724 | 0.27 | Why? |
| Disease Outbreaks | 9 | 2020 | 27595 | 0.27 | Why? |
| Cross Infection | 5 | 2018 | 8675 | 0.27 | Why? |
| Middle Aged | 34 | 2021 | 270681 | 0.26 | Why? |
| Immunogenicity, Vaccine | 1 | 2019 | 4624 | 0.26 | Why? |
| Time Factors | 9 | 2021 | 31397 | 0.26 | Why? |
| Leukocytes, Mononuclear | 3 | 2021 | 2115 | 0.24 | Why? |
| Virus Internalization | 1 | 2021 | 7921 | 0.23 | Why? |
| Cytokines | 3 | 2021 | 15010 | 0.23 | Why? |
| Body Temperature | 2 | 2017 | 875 | 0.22 | Why? |
| Immunoglobulin G | 5 | 2021 | 21571 | 0.22 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.21 | Why? |
| Sepsis | 1 | 2018 | 3517 | 0.21 | Why? |
| Pneumonia, Viral | 12 | 2021 | 243684 | 0.21 | Why? |
| Administration, Oral | 2 | 2018 | 2340 | 0.21 | Why? |
| Aged | 27 | 2021 | 215776 | 0.20 | Why? |
| Ki-67 Antigen | 1 | 2020 | 139 | 0.20 | Why? |
| Granzymes | 1 | 2020 | 197 | 0.20 | Why? |
| Perforin | 1 | 2020 | 136 | 0.20 | Why? |
| Klebsiella | 1 | 2019 | 35 | 0.20 | Why? |
| Immunoglobulin Variable Region | 1 | 2021 | 253 | 0.20 | Why? |
| Immunoglobulin Heavy Chains | 1 | 2021 | 222 | 0.20 | Why? |
| Anthrax | 1 | 2019 | 35 | 0.20 | Why? |
| Orientia tsutsugamushi | 1 | 2019 | 45 | 0.19 | Why? |
| Betacoronavirus | 9 | 2020 | 204454 | 0.19 | Why? |
| Leukocidins | 1 | 2018 | 47 | 0.19 | Why? |
| Complementarity Determining Regions | 1 | 2019 | 147 | 0.19 | Why? |
| Adolescent | 16 | 2021 | 86841 | 0.19 | Why? |
| Exotoxins | 1 | 2018 | 54 | 0.18 | Why? |
| Adenosine Monophosphate | 3 | 2020 | 5652 | 0.18 | Why? |
| Alanine | 3 | 2020 | 5687 | 0.18 | Why? |
| Cell Surface Display Techniques | 1 | 2019 | 170 | 0.18 | Why? |
| Serologic Tests | 4 | 2020 | 4359 | 0.18 | Why? |
| Camelus | 3 | 2018 | 1425 | 0.18 | Why? |
| Clonorchiasis | 1 | 2017 | 1 | 0.18 | Why? |
| Sparganosis | 1 | 2017 | 2 | 0.18 | Why? |
| Suspensions | 1 | 2018 | 63 | 0.18 | Why? |
| Emulsions | 1 | 2018 | 80 | 0.18 | Why? |
| Paragonimiasis | 1 | 2017 | 6 | 0.18 | Why? |
| Multivariate Analysis | 3 | 2018 | 5440 | 0.18 | Why? |
| Smallpox | 1 | 2019 | 96 | 0.17 | Why? |
| Endopeptidases | 1 | 2018 | 228 | 0.17 | Why? |
| Kuwait | 1 | 2018 | 306 | 0.17 | Why? |
| Antibodies, Helminth | 1 | 2017 | 48 | 0.17 | Why? |
| Microscopy, Electron, Transmission | 1 | 2020 | 605 | 0.17 | Why? |
| Medical History Taking | 1 | 2020 | 350 | 0.17 | Why? |
| Community-Acquired Infections | 3 | 2019 | 2328 | 0.17 | Why? |
| beta 2-Microglobulin | 1 | 2017 | 102 | 0.17 | Why? |
| Antibiotic Prophylaxis | 2 | 2018 | 399 | 0.17 | Why? |
| Fever of Unknown Origin | 1 | 2018 | 93 | 0.17 | Why? |
| HIV Infections | 3 | 2018 | 11620 | 0.17 | Why? |
| Drug Resistance, Multiple | 1 | 2018 | 156 | 0.17 | Why? |
| Cysticercosis | 1 | 2017 | 32 | 0.17 | Why? |
| Antiviral Agents | 6 | 2020 | 41703 | 0.16 | Why? |
| Aged, 80 and over | 14 | 2021 | 88759 | 0.16 | Why? |
| Viral Load | 2 | 2021 | 15850 | 0.16 | Why? |
| Vaccinia virus | 1 | 2019 | 346 | 0.16 | Why? |
| Single-Chain Antibodies | 1 | 2019 | 259 | 0.16 | Why? |
| Embolism | 1 | 2018 | 136 | 0.16 | Why? |
| Virus Replication | 1 | 2018 | 14331 | 0.16 | Why? |
| Injections, Intramuscular | 1 | 2019 | 800 | 0.16 | Why? |
| Immunophenotyping | 1 | 2021 | 1290 | 0.16 | Why? |
| Bacteriophages | 1 | 2019 | 268 | 0.16 | Why? |
| Vaccines, Synthetic | 2 | 2019 | 3231 | 0.16 | Why? |
| Tick-Borne Diseases | 1 | 2016 | 68 | 0.15 | Why? |
| Death, Sudden | 1 | 2018 | 160 | 0.15 | Why? |
| Odds Ratio | 2 | 2019 | 5861 | 0.15 | Why? |
| Particle Size | 1 | 2021 | 1052 | 0.15 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2019 | 449 | 0.15 | Why? |
| Compassionate Use Trials | 1 | 2020 | 632 | 0.15 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2020 | 724 | 0.15 | Why? |
| Antibodies, Bacterial | 1 | 2019 | 510 | 0.15 | Why? |
| Single-Blind Method | 1 | 2019 | 1283 | 0.14 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 2 | 2018 | 711 | 0.14 | Why? |
| Vancomycin | 1 | 2018 | 328 | 0.14 | Why? |
| Vero Cells | 4 | 2021 | 14117 | 0.14 | Why? |
| Purines | 1 | 2020 | 816 | 0.14 | Why? |
| Reverse Transcription | 1 | 2018 | 673 | 0.14 | Why? |
| Prothrombin Time | 1 | 2016 | 434 | 0.14 | Why? |
| Azetidines | 1 | 2020 | 722 | 0.14 | Why? |
| Escherichia coli | 2 | 2019 | 1547 | 0.14 | Why? |
| Hydrogen-Ion Concentration | 1 | 2018 | 993 | 0.13 | Why? |
| Antigens, Viral | 2 | 2021 | 6298 | 0.13 | Why? |
| Spleen | 1 | 2018 | 877 | 0.13 | Why? |
| Infusions, Intravenous | 1 | 2018 | 1224 | 0.13 | Why? |
| Travel | 4 | 2020 | 7220 | 0.13 | Why? |
| Reagent Kits, Diagnostic | 2 | 2021 | 2149 | 0.13 | Why? |
| Healthy Volunteers | 1 | 2019 | 1444 | 0.13 | Why? |
| Microscopy, Electron | 1 | 2016 | 830 | 0.13 | Why? |
| Hyperbaric Oxygenation | 1 | 2016 | 268 | 0.13 | Why? |
| Primary Prevention | 1 | 2020 | 778 | 0.12 | Why? |
| Real-Time Polymerase Chain Reaction | 5 | 2021 | 11367 | 0.12 | Why? |
| History, 21st Century | 2 | 2017 | 1849 | 0.12 | Why? |
| Risk Factors | 10 | 2019 | 71621 | 0.12 | Why? |
| beta-Lactamases | 1 | 2019 | 759 | 0.12 | Why? |
| Chemokine CXCL10 | 1 | 2016 | 565 | 0.12 | Why? |
| Alanine Transaminase | 1 | 2018 | 1329 | 0.12 | Why? |
| Sexual Partners | 1 | 2017 | 612 | 0.12 | Why? |
| Animals | 10 | 2021 | 78931 | 0.12 | Why? |
| Data Accuracy | 1 | 2018 | 715 | 0.12 | Why? |
| Alleles | 1 | 2018 | 1557 | 0.12 | Why? |
| Stem Cell Transplantation | 1 | 2017 | 531 | 0.12 | Why? |
| CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.12 | Why? |
| Intensive Care Units, Neonatal | 1 | 2018 | 749 | 0.12 | Why? |
| Sulfonamides | 1 | 2020 | 1294 | 0.11 | Why? |
| Polymerase Chain Reaction | 2 | 2018 | 6740 | 0.11 | Why? |
| Staphylococcus aureus | 1 | 2018 | 844 | 0.11 | Why? |
| Aspartate Aminotransferases | 1 | 2018 | 1394 | 0.11 | Why? |
| Kinetics | 2 | 2021 | 3238 | 0.11 | Why? |
| Pneumonia | 3 | 2021 | 5652 | 0.11 | Why? |
| Asymptomatic Infections | 2 | 2020 | 7218 | 0.11 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.11 | Why? |
| Clostridium Infections | 1 | 2018 | 595 | 0.11 | Why? |
| Pandemics | 12 | 2021 | 389249 | 0.11 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.11 | Why? |
| Antibody Affinity | 1 | 2015 | 1078 | 0.10 | Why? |
| Sex Distribution | 1 | 2018 | 2083 | 0.10 | Why? |
| Chemokines | 1 | 2016 | 1095 | 0.10 | Why? |
| Prospective Studies | 4 | 2019 | 43301 | 0.10 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.10 | Why? |
| Creatinine | 1 | 2016 | 1443 | 0.10 | Why? |
| Pyrazoles | 1 | 2020 | 1791 | 0.10 | Why? |
| Measles | 1 | 2017 | 608 | 0.10 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2021 | 2262 | 0.10 | Why? |
| Dose-Response Relationship, Drug | 1 | 2019 | 3776 | 0.10 | Why? |
| Retrospective Studies | 11 | 2021 | 105322 | 0.10 | Why? |
| Drug Prescriptions | 1 | 2018 | 1062 | 0.10 | Why? |
| Severity of Illness Index | 6 | 2021 | 48226 | 0.10 | Why? |
| Phylogeny | 2 | 2020 | 13341 | 0.09 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 1510 | 0.09 | Why? |
| Seroconversion | 1 | 2019 | 2515 | 0.09 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.09 | Why? |
| DNA, Viral | 1 | 2019 | 2521 | 0.09 | Why? |
| Delayed Diagnosis | 1 | 2018 | 1529 | 0.09 | Why? |
| Homosexuality, Male | 1 | 2017 | 1158 | 0.09 | Why? |
| Intention | 1 | 2017 | 1380 | 0.09 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.09 | Why? |
| Age Distribution | 1 | 2018 | 3567 | 0.09 | Why? |
| Civil Defense | 1 | 2020 | 1687 | 0.09 | Why? |
| Mass Screening | 2 | 2018 | 8005 | 0.09 | Why? |
| Multiple Myeloma | 1 | 2017 | 1064 | 0.09 | Why? |
| Seroepidemiologic Studies | 3 | 2019 | 10017 | 0.08 | Why? |
| Cross-Sectional Studies | 5 | 2021 | 53120 | 0.08 | Why? |
| Family Characteristics | 1 | 2018 | 2551 | 0.08 | Why? |
| Protein Binding | 2 | 2021 | 11430 | 0.08 | Why? |
| Symptom Assessment | 1 | 2021 | 4967 | 0.08 | Why? |
| Antibodies, Monoclonal | 3 | 2021 | 8041 | 0.08 | Why? |
| Diagnosis, Differential | 2 | 2018 | 7220 | 0.08 | Why? |
| Leukocyte Count | 1 | 2016 | 3178 | 0.08 | Why? |
| Sequence Analysis, RNA | 1 | 2016 | 2290 | 0.08 | Why? |
| Interferon-gamma | 1 | 2016 | 2711 | 0.08 | Why? |
| RNA, Viral | 4 | 2018 | 32276 | 0.08 | Why? |
| Fever | 3 | 2020 | 7795 | 0.08 | Why? |
| Incidence | 3 | 2017 | 25622 | 0.08 | Why? |
| Infant, Newborn | 4 | 2021 | 23105 | 0.08 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.07 | Why? |
| Thrombocytopenia | 1 | 2019 | 2093 | 0.07 | Why? |
| Infant | 5 | 2021 | 30274 | 0.07 | Why? |
| Lung | 3 | 2020 | 31049 | 0.07 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.07 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.07 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.07 | Why? |
| Disease Progression | 3 | 2020 | 13580 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2021 | 3892 | 0.07 | Why? |
| Hematologic Neoplasms | 1 | 2018 | 2105 | 0.07 | Why? |
| Aerosols | 1 | 2021 | 5393 | 0.07 | Why? |
| Child, Preschool | 5 | 2021 | 36283 | 0.07 | Why? |
| Immunoassay | 1 | 2020 | 4485 | 0.07 | Why? |
| Zika Virus Infection | 1 | 2017 | 1920 | 0.06 | Why? |
| Dyspnea | 1 | 2016 | 3847 | 0.06 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.06 | Why? |
| Disease Management | 1 | 2021 | 6841 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 5277 | 0.06 | Why? |
| Specimen Handling | 1 | 2021 | 6190 | 0.06 | Why? |
| Child | 7 | 2021 | 70012 | 0.06 | Why? |
| Oxygen Inhalation Therapy | 3 | 2020 | 3629 | 0.06 | Why? |
| Hypertension | 2 | 2021 | 8895 | 0.06 | Why? |
| Tuberculosis | 1 | 2018 | 2895 | 0.06 | Why? |
| Evolution, Molecular | 1 | 2016 | 3691 | 0.06 | Why? |
| Aneurysm, Infected | 1 | 2020 | 36 | 0.05 | Why? |
| Clone Cells | 1 | 2021 | 312 | 0.05 | Why? |
| Serine-Arginine Splicing Factors | 1 | 2019 | 14 | 0.05 | Why? |
| Neutrophils | 1 | 2016 | 5476 | 0.05 | Why? |
| Prodromal Symptoms | 1 | 2020 | 133 | 0.05 | Why? |
| Lepidoptera | 1 | 2018 | 26 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.05 | Why? |
| Double-Blind Method | 2 | 2020 | 5988 | 0.05 | Why? |
| Smallpox Vaccine | 1 | 2019 | 46 | 0.05 | Why? |
| Bioterrorism | 1 | 2019 | 105 | 0.05 | Why? |
| Length of Stay | 1 | 2017 | 11042 | 0.05 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.05 | Why? |
| Seoul | 1 | 2019 | 206 | 0.05 | Why? |
| Surge Capacity | 2 | 2020 | 894 | 0.05 | Why? |
| Financial Support | 1 | 2020 | 170 | 0.05 | Why? |
| Gene Library | 1 | 2019 | 234 | 0.05 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2017 | 5002 | 0.05 | Why? |
| Injection Site Reaction | 1 | 2019 | 124 | 0.05 | Why? |
| Interleukin-6 | 1 | 2016 | 7522 | 0.05 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.04 | Why? |
| AIDS Serodiagnosis | 1 | 2018 | 64 | 0.04 | Why? |
| Vancomycin Resistance | 1 | 2018 | 55 | 0.04 | Why? |
| Autografts | 1 | 2017 | 78 | 0.04 | Why? |
| Viral Vaccines | 1 | 2019 | 7560 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2018 | 264 | 0.04 | Why? |
| Biomarkers | 1 | 2021 | 23361 | 0.04 | Why? |
| Antigens, Helminth | 1 | 2017 | 54 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2021 | 6543 | 0.04 | Why? |
| Hospital Mortality | 2 | 2020 | 22087 | 0.04 | Why? |
| World Health Organization | 2 | 2020 | 4213 | 0.04 | Why? |
| Probability | 1 | 2021 | 923 | 0.04 | Why? |
| Bortezomib | 1 | 2017 | 125 | 0.04 | Why? |
| Reference Standards | 1 | 2021 | 1163 | 0.04 | Why? |
| CHO Cells | 1 | 2019 | 831 | 0.04 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 2984 | 0.04 | Why? |
| Patient Isolation | 2 | 2020 | 3182 | 0.04 | Why? |
| Administration, Intravenous | 1 | 2020 | 1115 | 0.04 | Why? |
| Cricetulus | 1 | 2019 | 936 | 0.04 | Why? |
| Ticks | 1 | 2016 | 107 | 0.04 | Why? |
| Species Specificity | 1 | 2020 | 1356 | 0.04 | Why? |
| Prevalence | 4 | 2018 | 25773 | 0.04 | Why? |
| Virulence Factors | 1 | 2018 | 338 | 0.04 | Why? |
| False Positive Reactions | 1 | 2021 | 1338 | 0.04 | Why? |
| Cloning, Molecular | 1 | 2019 | 1036 | 0.04 | Why? |
| Pharyngitis | 1 | 2020 | 687 | 0.04 | Why? |
| Mesocricetus | 1 | 2021 | 1847 | 0.04 | Why? |
| Drug Synergism | 1 | 2018 | 833 | 0.04 | Why? |
| Forced Expiratory Volume | 1 | 2018 | 632 | 0.04 | Why? |
| Janus Kinase Inhibitors | 1 | 2020 | 682 | 0.04 | Why? |
| Ferrets | 1 | 2021 | 1201 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2018 | 9044 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2021 | 9537 | 0.03 | Why? |
| Measles-Mumps-Rubella Vaccine | 1 | 2017 | 282 | 0.03 | Why? |
| Interrupted Time Series Analysis | 1 | 2018 | 868 | 0.03 | Why? |
| Endemic Diseases | 1 | 2018 | 480 | 0.03 | Why? |
| Geography | 1 | 2020 | 1801 | 0.03 | Why? |
| Immunoglobulins | 1 | 2019 | 811 | 0.03 | Why? |
| Risk-Taking | 1 | 2017 | 508 | 0.03 | Why? |
| Administration, Inhalation | 1 | 2019 | 1647 | 0.03 | Why? |
| Logistic Models | 2 | 2019 | 9089 | 0.03 | Why? |
| Molecular Epidemiology | 1 | 2018 | 1638 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.03 | Why? |
| Propensity Score | 1 | 2021 | 2690 | 0.03 | Why? |
| Treatment Failure | 1 | 2018 | 2106 | 0.03 | Why? |
| C-Reactive Protein | 2 | 2020 | 7972 | 0.03 | Why? |
| Area Under Curve | 1 | 2019 | 2564 | 0.03 | Why? |
| Nasopharynx | 2 | 2021 | 10224 | 0.03 | Why? |
| Myalgia | 1 | 2017 | 1015 | 0.03 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.03 | Why? |
| Cricetinae | 1 | 2019 | 3344 | 0.03 | Why? |
| Respiration, Artificial | 3 | 2020 | 22116 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.03 | Why? |
| Data Collection | 1 | 2020 | 1769 | 0.03 | Why? |
| Macaca mulatta | 1 | 2021 | 3716 | 0.03 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2021 | 13720 | 0.03 | Why? |
| Protein Conformation | 1 | 2021 | 4386 | 0.02 | Why? |
| Contact Tracing | 2 | 2020 | 8448 | 0.02 | Why? |
| Treatment Outcome | 3 | 2020 | 51732 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.02 | Why? |
| Health Personnel | 1 | 2019 | 29646 | 0.02 | Why? |
| Headache | 1 | 2019 | 2257 | 0.02 | Why? |
| Emigrants and Immigrants | 1 | 2017 | 888 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.02 | Why? |
| Diabetes Complications | 1 | 2021 | 2358 | 0.02 | Why? |
| Fatigue | 1 | 2019 | 2479 | 0.02 | Why? |
| Sexual Behavior | 1 | 2017 | 1322 | 0.02 | Why? |
| Tuberculosis, Pulmonary | 1 | 2018 | 1171 | 0.02 | Why? |
| Diarrhea | 1 | 2020 | 2743 | 0.02 | Why? |
| Lymphopenia | 1 | 2020 | 2669 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2018 | 5814 | 0.02 | Why? |
| Exanthema | 1 | 2017 | 1097 | 0.02 | Why? |
| Protein Domains | 1 | 2021 | 6563 | 0.02 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2020 | 3444 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2019 | 6049 | 0.02 | Why? |
| Saudi Arabia | 1 | 2018 | 4423 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.02 | Why? |
| ROC Curve | 1 | 2019 | 6024 | 0.02 | Why? |
| Models, Molecular | 1 | 2021 | 7616 | 0.02 | Why? |
| Influenza, Human | 1 | 2011 | 10779 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Cough | 1 | 2020 | 4891 | 0.02 | Why? |
| Survivors | 1 | 2018 | 2619 | 0.02 | Why? |
| Cross Reactions | 1 | 2017 | 4374 | 0.02 | Why? |
| Renin-Angiotensin System | 1 | 2021 | 3661 | 0.02 | Why? |
| Zika Virus | 1 | 2017 | 1924 | 0.02 | Why? |
| National Health Programs | 1 | 2011 | 807 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2021 | 11304 | 0.02 | Why? |
| B-Lymphocytes | 1 | 2019 | 4418 | 0.02 | Why? |
| Asia | 1 | 2011 | 2399 | 0.02 | Why? |
| Developing Countries | 1 | 2020 | 4283 | 0.02 | Why? |
| Decision Making | 1 | 2018 | 3132 | 0.02 | Why? |
| Seasons | 1 | 2016 | 4071 | 0.02 | Why? |
| Zoonoses | 1 | 2018 | 3034 | 0.02 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.02 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3832 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Population Surveillance | 1 | 2020 | 4967 | 0.02 | Why? |
| Public Health | 2 | 2019 | 16359 | 0.02 | Why? |
| Disease Models, Animal | 1 | 2021 | 10998 | 0.02 | Why? |
| Universities | 1 | 2017 | 4374 | 0.01 | Why? |
| Pregnancy | 2 | 2017 | 23879 | 0.01 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 5002 | 0.01 | Why? |
| Genetic Variation | 1 | 2016 | 3919 | 0.01 | Why? |
| Saliva | 1 | 2017 | 4679 | 0.01 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2018 | 8248 | 0.01 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.01 | Why? |
| Internet | 1 | 2017 | 6204 | 0.01 | Why? |
| Health Behavior | 1 | 2017 | 4449 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2021 | 14232 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2019 | 15978 | 0.01 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.01 | Why? |
| Genome, Viral | 1 | 2016 | 13157 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |